BMS Unleashes AI Power with Nvidia SuperPOD | Tech News

Bristol Myers Squibb just pulled off a groundbreaking move in drug discovery by acquiring Nvidia’s cutting-edge DGX SuperPOD, the first of its kind in life sciences, built on the powerful Vera Rubin architecture. With eight high-performance systems, BMS is turbocharging its AI-driven research to accelerate medicine development, training custom models and running massive predictions across all programs. This leap not only upgrades their computational muscle but also gives scientists direct access to faster, more efficient tools—cutting down bottlenecks and letting them evaluate dozens of drug candidates instead of just ten. Using AI’s “Predict First” approach, they’re filtering out failures early, focusing lab resources on high-potential molecules, and aiming to slash clinical trial timelines by up to 50%. This isn’t just raw power—it’s smarter, faster science. Listen in comfort:Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/f5e3725199fbd132